About Thymosin Alpha-1 - Immune Support Peptide

Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that acts as a master immune system regulator. It strengthens your immune defenses by ramping up T-cell, B-cell, and natural killer (NK) cell activity to fight infections, while also helping calm overactive immune responses. It's most commonly used for chronic infections (like Lyme or viral issues), immune deficiency, and general immune support during illness.

WHAT THE RESEARCH SHOWS

Research on Thymosin Alpha-1 (TA1) is a 28-amino acid peptide naturally produced by the thymus gland—centers on its powerful ability to train, balance, and restore the immune system. Here is what clinical and preclinical studies show:
* T-Cell Maturation & Activation: It plays a pivotal role in the differentiation of stem cells into mature, functioning T-cells. Studies show it significantly increases cytotoxic T-cells, helper T-cells (Th1), and Natural Killer (NK) cell activity, drastically improving the body's ability to hunt down pathogens and abnormal cells.
* Immune Modulator (Not Just a "Booster"): Unlike synthetic stimulants that can push an immune system into overdrive, research shows Tα1 acts as a true modulator. It ramps up immune defenses when your body is fighting chronic infection, but also upregulates regulatory T-cells (Tregs) to dampen systemic inflammation and prevent autoimmune flare-ups or cytokine storms. Antiviral & Antimicrobial Defense: It is clinically approved in over 30 countries (under the trade name Zadaxin*) for treating chronic Hepatitis B and C, and has been extensively studied as a frontline therapy for severe respiratory infections, sepsis, and stubborn viral loads.
* Oncology Adjunct & Tissue Recovery: Research highlights its ability to counteract chemotherapy-induced immunosuppression, protecting white blood cell counts and restoring immune surveillance in immunocompromised patients.
* Exceptional Safety Profile: Because it is an endogenous peptide the body naturally creates in the thymus, clinical trials consistently demonstrate an extremely low incidence of adverse effects.

STUDIES

• Sepsis (meta-analysis level). A 2025 meta-analysis of 11 randomised trials (about 1,900 patients) found Tα1 significantly reduced 28-day mortality, cutting the odds of dying by about 27% (OR 0.73, p = 0.003).
  • Earlier small studies had shown improved immune function, and an expert consensus recommended Tα1 for sepsis-related immune suppression.
• Other clinical uses abroad. These include sepsis care, COPD flare-ups, reducing infection risk in pancreatitis, boosting vaccine response in older adults, and immune recovery after illness. Recent trials in 2024 and 2025 strengthened the COPD and pancreatitis evidence.
• Vaccine response. International trial data show improved response to flu and hepatitis B vaccines in older or immunosuppressed adults.
• Safety. Four decades of trial data show a low rate of adverse events.

Approval and scale

• Zadaxin is approved for hepatitis B, hepatitis C and as an immune adjunct in cancer patients. One source names China and Italy among the approving countries.
• More than 11,000 people have taken part in over 30 clinical trials, and post-marketing surveillance covers more than 600,000 patients.

LINKS

• Outliyr – Thymosin alpha-1 report
• Peptide Journal – Thymosin alpha-1 clinical evidence review
• Peptide Protocol Wiki – Thymosin alpha-1 research

Lyophilised powder